摘要
贝伐珠单抗是一种重组人源化免疫球蛋白G1单克隆抗体,可通过抑制血管内皮生长因子活性及抗血管生成,达到抑制肿瘤生长的目的,目前已广泛用于结直肠癌、肺癌、卵巢癌等多种肿瘤的治疗,尤其是通过与基础化疗结合,能显著提高治疗的有效率以及延长肿瘤患者的无进展生存期和总生存期。综述贝伐珠单抗的抗肿瘤作用机制、在不同肿瘤治疗中的应用、用于肿瘤治疗时机与疗效差异以及不良反应和防治。
Bevacizumab is a recombinant humanized monoelonal IgG1 antibody that suppresses tumor growth by inhibiting vascular endothelial growth factor and angingenesis. It has been used widely in the treatment of several tumors, such as colorectal, lung and ovarian cancers, especially in combination of basic chemotherapy, which has been proved to significantly improve response rate, progression-free survival and overall survival. The antimmor mechanism, application in the treatment of tumors, timing of intervention and the difference of efficacy as well as adverse reactions and their prevention and control for bevacizumab were reviewed.
出处
《药学进展》
CAS
2015年第7期525-532,共8页
Progress in Pharmaceutical Sciences
关键词
贝伐珠单抗
单克隆抗体
血管生成
抗肿瘤活性
无进展生存期
总生存期
bevacizumab
monoclonal antibody
angiogenesis
antitumor activity
progression-free survival
overall survival
